NEW STUDY IN JOURNAL OF UROLOGY SHOWS UROVYSION DNA TEST SUPERIOR TO STANDARD CYTOLOGY IN DIAGNOSING BLADDER CANCER IN AT-RISK PATIENTS

A study published in the July 2006 edition of Journal of Urology has shown that UroVysio, a DNA-based urine test that detects important genetic changes in bladder cells, has almost twice the sensitivity of conventional urine cytology tests, the current gold standard, as an aid for the initial diagnosis of bladder cancer in patients with hematuria (blood in urine) suspected of having bladder cancer. Sensitivity refers to the likelihood that a patient with bladder cancer will have a positive test result and is a standard indicator of the predictive value of a diagnostic test.
Abbott Laboratories